During the past decade, Hamatologisch - Onkologische Praxis Wurzburg conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 4 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 2 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hamatologisch - Onkologische Praxis Wurzburg" #1 sponsor was "German CLL Study Group" with 10 trials, followed by "Hoffmann-La Roche" with 5 trials sponsored, "Celgene" with 2 trials sponsored, "Celgene Corporation" with 1 trials sponsored and "Genentech, Inc." with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hamatologisch - Onkologische Praxis Wurzburg" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Cancer Trials Ireland" with 1 trials as a collaborator and "Genentech, Inc." with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Hamatologisch - Onkologische Praxis Wurzburg" are "Chronic Lymphocytic Leukemia" (5 trials), "Breast Cancer" (3 trials), "Chronic Lymphoid Leukemia" (3 trials), "Leukemia" (3 trials) and "Anemia" (1 trials). Many other conditions were trialed in "Hamatologisch - Onkologische Praxis Wurzburg" in a lesser frequency.

Most popular intervention types in "Hamatologisch - Onkologische Praxis Wurzburg" are "Drug" (18 trials), "Biological" (8 trials), "Procedure" (2 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Obinutuzumab" (4 trials), "Cyclophosphamide" (3 trials), "Fludarabine" (3 trials), "Rituximab" (3 trials) and "Bendamustine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hamatologisch - Onkologische Praxis Wurzburg" are 21 trials for "All" genders.

Currently, there are NaN active trials in "Hamatologisch - Onkologische Praxis Wurzburg". undefined are not yet recruiting, 3 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Hamatologisch - Onkologische Praxis Wurzburg, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hamatologisch - Onkologische Praxis Wurzburg, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".